Validation of the Lemann Index

  • Research type

    Research Study

  • Full title

    Validation of the Lemann Index:a Prospective, Cross-sectional, Multicenter, Observational, International Study

  • IRAS ID

    231027

  • Contact name

    Naila Arebi

  • Contact email

    naila.arebi@imperial.ac.uk

  • Sponsor organisation

    London Northwest Healthcare NHS Trust

  • Duration of Study in the UK

    0 years, 7 months, 31 days

  • Research summary

    The aim of the study is to validate the Lemann index, the first tool assessing digestive damage in patients suffering from Crohn’s disease (CD). Crohn's disease is a chronic inflammatory gut disorder which can cause damage to the gut. Damage manifests as loss of function due to scarring or creation of tracts. Damage may require resection of parts of the gut. There is no collective measure of gut damage in Crohn's disease. We want study whether a scoring system called the Lemann index is a reliable measure of progressive damage in Crohn's disease. This is important because we want to be able to use this to study the effect of new drugs. All patients who have Crohn's disease and have undergone recent investigation are eligible. The study will be conducted in two NHS hospitals in the UK, several European and an American hospital. It is short study of <6 months. There is no intervention. We want to collect the results of the investigations that patients undergo and place specific readings into a chart to generate a Lemann index score.

  • REC name

    East of Scotland Research Ethics Service REC 2

  • REC reference

    17/ES/0106

  • Date of REC Opinion

    2 Oct 2017

  • REC opinion

    Further Information Favourable Opinion